12,372 trials
Spinal Muscular Atrophy
Primary: Overview of Treatment-emergent Adverse Events by Age Subgroup — 27; 13; 4; 0 Participants
Arthritis Juvenile Idiopathic
Primary: Time to Systemic Juvenile Idiopathic Arthritis (sJIA) Disease Flare: Double-Blind Phase — NA; 295.0 Days — p== 0.1171
Hypertension
Primary: Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12 — -4.0; 1.4; -1.5; 0.4 mmHg — p=<.0001
Haemophilia B
Primary: Haemostatic Effect of Nonacog Beta Pegol When Used for Treatment of Bleeding Episodes During on Demand and Prophylaxis (PPX) — 203; 3; 26; 8 Bleeding Episodes
Familial Hypercholesterolemia - Homozygous
Primary: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) — -21.6; 11.7 percent change in LDL-C
Obesity Associated With Defects in Leptin-melanocortin Pathway
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 198 Participants
Post Traumatic Stress Disorder
Primary: Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score — -16.53; -18.28; -17.57 score on a scale — p=0.5165
Papillomavirus Infections
Primary: Seroconversion Percentages for the HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 — 100.0; 100.0; 100.0; 100.0 Percentage of Participants
Open Angle Glaucoma · Ocular Hypertension
Primary: Mean IOP Reduction From Time-Matched Baseline at the 8AM and 4PM Time-Points at Week 2, Week 6, and Month 3 — -9.43; -8.85; -8.01; -7.11 mmHg
Osteoporosis, Postmenopausal
Primary: Percent Change From Baseline in LS BMD at Month 12 to Demonstrate Comparable Efficacy of AVT03 and Prolia®. — 5.3; 5.18 Percent Change From Baseline in LS BMD
Status Epilepticus
Primary: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE — 79.59…
Influenza
Primary: Hemagglutination Inhibition (HI) Geometric Mean Titers (GMT) Post-vaccination (Day 28) of Each Vaccine Reference Virus — 584.2; 342.8; 217.4; 169.0 antibody titer…
Sedation
Primary: Percentage of Time of Adequately Maintained Sedation Depth up to 48 Hours (± 6 Hours) — 62.37; 68.94 Percentage of time
Alzheimer Disease
Primary: Change From Baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12) — 2.79; 3.19 score on a scale — p=0.4308
SARS-CoV-2
Primary: Geometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15 — 1180.55; 1300.25 AU/mL